Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.
Limited data are available on the determinants of homocysteinemia or the association between plasma homocysteine (Hcy) levels and prevalent cardiovascular disease (CVD) in maintenance dialysis patients. We assessed etiology of renal failure, residual renal function and dialysis adequacy-related variables, and vitamin status, as determinants of fasting total plasma homocysteine (Hcy) in 75 maintenance dialysis patients. We also assessed the potential interactive effect on plasma Hcy of folate status and a common mutation (ala to val; homozygous val-val frequency approximately 10%) in methylenetetrahydrofolate reductase (MTHFR), a folate-dependent enzyme crucial for the remethylation of homocysteine (Hcy) to methionine. Lastly, we evaluated whether the Hcy levels differed amongst these patients in the presence or absence of prevalent CVD, after adjustment for the traditional CVD risk factors. Fasting total plasma Hcy, folate, pyridoxal 5'-phosphate (PLP; active B6), B12, creatinine, glucose, total and HDL cholesterol levels, and presence of the ala to val MTHFR mutation were determined, and clinical CVD and CVD risk factor prevalence were ascertained. General linear modelling/analysis of covariance revealed: (1) folate status and serum creatinine were the only significant independent predictors of fasting Hcy; (2) there was a significant interaction between presence of the val mutation and folate status, i.e., among patients with plasma folate below the median (< 29.2 ng/ml), geometric mean Hcy levels were 33% greater (29.0 vs. 21.8 microM, P = 0.012) in the pooled homozygotes (val-val) and heterozygotes (ala-val) for the ala to val mutation, vs. normals (ala-ala); (3) there was no association between prevalent CVD and plasma Hcy. Given potentially intractable survivorship effects, prospective cohort studies will be required to clarify the relationship between plasma Hcy or any putative CVD risk factor, and incident CVD in dialysis patients. If a positive association between plasma Hcy and incident CVD can be established in maintenance dialysis patients, the current data provide a rationale for additional folic acid supplementation in this patient population.
Bostom
A G
AG
Vitamin Bioavailability Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts New England Medical Center, Boston MA 02111, USA.
Shemin
D
D
Lapane
K L
KL
Nadeau
M R
MR
Sutherland
P
P
Chan
J
J
Rozen
R
R
Yoburn
D
D
Jacques
P F
PF
Selhub
J
J
Rosenberg
I H
IH
D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D015897:Comorbidity; D003404:Creatinine / Q000097:blood; D004252:DNA Mutational Analysis; D005260:Female; D005492:Folic Acid / Q000097:blood*; D018149:Glucose Intolerance; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics*; D010530:Peritoneal Dialysis; D012150:Polymorphism, Restriction Fragment Length; D015995:Prevalence; D006435:Renal Dialysis; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology; D014805:Vitamin B 12 / Q000097:blood
D008076:Cholesterol, HDL; D006710:Homocysteine; D005492:Folic Acid; D003404:Creatinine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D014805:Vitamin B 12